Drug composite containing troxerutin and ADP receptor antagonist

A receptor antagonist and composition technology, applied in the field of new pharmaceutical compositions, can solve the problems such as no troxerutin reported in the literature, and achieve inhibition of platelet aggregation, reduction of bleeding rate, good anti-platelet activity and anti-platelet effect. The effect of suppository activity

Active Publication Date: 2010-02-03
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] No literature reports related to the combination of troxerutin and ticlopidine or clopidogrel or prasugrel were found in domestic and foreign public publications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug composite containing troxerutin and ADP receptor antagonist
  • Drug composite containing troxerutin and ADP receptor antagonist
  • Drug composite containing troxerutin and ADP receptor antagonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Embodiment 1 common tablet

[0015] Troxerutin 180g

[0016] Prasugrel Maleate 2g

[0017] Microcrystalline Cellulose 500g

[0018] Lactose 40g

[0019] 10% starch slurry appropriate amount

[0020] Magnesium stearate 8g

[0021] Preparation Process:

[0022] Troxerutin, prasugrel maleate, microcrystalline cellulose, and lactose were weighed and mixed uniformly. In addition, add an appropriate amount of 10% starch slurry to the mixed powder, mix evenly, make soft material, pass through a 18-mesh nylon sieve to make wet granules, and dry at about 60°C. The moisture content of the dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

Embodiment 2

[0023] Embodiment 2 common tablet

[0024] Troxerutin 60g

[0025] Clopidogrel Sulfate 5g

[0026] Starch 140g

[0027] Dextrin 120g

[0028] 50% ethanol appropriate amount

[0029] Magnesium Stearate 1.0g

[0030] Preparation Process:

[0031]Troxerutin, clopidogrel sulfate, starch and dextrin were weighed and mixed uniformly. In addition, an appropriate amount of 50% ethanol is added to the mixed powder, mixed evenly, made into soft material, passed through a 18-mesh nylon sieve to make wet granules, dried at about 60°C, and the moisture content of the dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

Embodiment 3

[0032] Embodiment 3 common tablet

[0033] Troxerutin 200g

[0034] Ticlopidine hydrochloride 50g

[0035] Microcrystalline Cellulose 500g

[0036] Lactose 40g

[0037] 10% starch slurry appropriate amount

[0038] Magnesium stearate 8g

[0039] Preparation Process:

[0040] Troxerutin, ticlopidine hydrochloride, microcrystalline cellulose and lactose were weighed and mixed uniformly. In addition, add an appropriate amount of 10% starch slurry to the mixed powder, mix evenly, make soft materials, pass through a 18-mesh nylon sieve to make wet granules, and dry at about 60°C. The moisture content of dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to a new drug composite, in particular to a drug composite which adopts troxerutin and ADP receptor antagonist as active ingredients. In order to find a composite drug compositefor curing thrombotic diseases which can not only keep the fast and forceful anticoagulation activity, but also effectively reduce the bleeding risk, the inventor finds that using both troxerutin andADP receptor antagonist for inhibiting the thrombosis has unexpected effect and extremely good synergistic effect through serious and repeated experiments and the mixed use of the both drugs can not only increase the antithrombotic function, but also reduce the bleeding risk when using ADP receptor antagonist so that the use of both drugs has better and more effective anticoagulation activity andfaster function.

Description

technical field [0001] The invention belongs to a new pharmaceutical composition, in particular to a pharmaceutical composition comprising troxerutin and an ADP (adenosine diphosphate) receptor antagonist as active ingredients. Background technique [0002] Troxerutin belongs to bioflavonoids and is the most important active ingredient in oxerutin. Since 1960, Europe has used oxerutin to treat varicose veins. Hydroxyrutin is not a single substance. It is a group of chemical components derived from naturally occurring bioflavonoids called rutin. The current domestic product is obtained by hydroxyethylation of rutin. Troxerutin (7,3,4-trihydroxyethyl rutin )-based mixture of hydroxyethyl rutin, the content of troxerutin is not less than 80% (National Drug Standard-2002 issued by the State Drug Administration). Hydroxyrutin has a strong ability to transport oxygen and energy to microvessels, and can deliver oxygen and energy to various cells in the body. If the pressure is in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/4365A61P7/02
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap